Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data
The departure of U.K. Science Minister Patrick Vallance is a blow for U.K. biotech. On the latest BioCentury This Week podcast, BioCentury’s...
Radio and PodcastLive Radio & Podcasts
Science & Medicine
BioCentury This Week
A trusted and essential partner to the biopharmaceutical industry, providing 27 years of in-depth research, analysis and data on innovation and excellence —from biology to the patient.
BioCentury This Week Podcast Guide
Listen to BioCentury This Week, a Science & Medicine podcast by BioCentury. Stream 388 episodes in English, follow new audio stories, and play episodes online on Radio and Podcast.
Show Topic
Browse this show under Science & Medicine podcasts.
Episodes
20 episodes are loaded now from a catalog of 388. More episodes can be opened from this page.
Discover More
Explore Science & Medicine podcasts, South Korea podcasts and English podcasts.
Episodes
20 of 388 episodes
Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson
After nearly three years of sluggish job growth, hiring is turning a corner in the U.S. life sciences industry, while the talent pool is exp...
Ep. 376 - M&A momentum: 3Q public markets preview
M&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts disc...
Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech
Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the lates...
Ep. 374 - Parkinson's deep dive & FDA trial reforms
New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell...
Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first
AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On...
Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’...
Ep. 371 - Moving faster at the academia-industry interface
Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too. From...
Ep. 370 - Calmer waters for FDA; Servier, Lilly deals
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On...
Ep. 369 - ASCO advances, China innovation & U.S. science under threat
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the late...
Ep. 368 - ASCO Preview, China Policy, ADC Linkers
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight...
Ep. 367 - FDA, obesity targets and the rise of DACs
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the la...
Ep. 366 - Europe's need for speed: Bio€quity takeaways
China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCent...
Ep. 365 - Thin ice for Makary, redosing AAVs
Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commis...
Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies
UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candi...
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the fo...
Ep. 362 - AACR: Data and de-risking
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Researc...
Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDA...
Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar polici...
Ep. 359 - 2Q markets preview, tariffs and biotech takeouts
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing...